高聚金葡素联合化疗药物介入治疗中晚期肝癌临床疗效观察  

Curative Effect of Combination Therapy with Highly Agglutinative Staphylococcin in Interventional Treatment for Hepatic Tumors

作　　者：陈君辉[1] 陈励[1] 胡大武[1] 任胜辉[1] 段天红[1] 文永君[1] 杨承莲[1] 

机构地区：[1]四川省肿瘤医院影像科介入病区,成都市610041

出　　处：《中国肿瘤临床》1999年第8期622-623,共2页Chinese Journal of Clinical Oncology

摘　　要：目的 :观察超抗原抗癌剂高聚金葡素 (HighlyAgglutinativeStaphylococcin ,HASL)联合化疗药物介入治疗中晚期肝癌的疗效。方法 :10 8例中晚期肝癌患者随机分为治疗组 48例 ,给予HASL加化疗药物治疗。对照组 6 0例单纯给予化疗药物治疗。结果 :治疗组瘤体缩小近期有效率为 5 8.3% ,较对照组 2 6 .6 %有显著性差异 (P <0 .0 5 ) ;并且治疗组白细胞下降率和消化道症状明显改善 ,较对照组有显著性差异 (P <0 .0 5 )。结论 :HASL联合化疗药物介入治疗肝癌有明显的协同作用。HASL在降低化疗药物的毒副反应 ,提高机体的免疫功能等方面均有显著的疗效。Objective:To evaluate the efficacy of combination therapy with highly Agglutinative Staphylococcin (HAS) via transcatheter hepatic arterial infusion for advanced hepatic tumors. Methods: One hundred-eight cases were divided randomly into treatment group 48 cases (chemotherapy +HAS) and control group 60 cases (chemotherapy only). Results: The total effective rate of the treatment group was 58.3%, and that of the control group was 26.6%with significant difference ( P < 0.05). The occurrence of gastrointestinal symptoms and WBC decrease rate in the treatment group was lower than that in control group ( P < 0.05). Conclusion: As combination therapy in the treatment of hepatic cancer, HAS plays an assistant role for the anti-tumor result, it also can reduce the side effects caused by chemotherapy and enhance immune function.

关 键 词：高聚金葡素 肝肿瘤 药物疗法 介入疗法 

分 类 号：R735.705[医药卫生—肿瘤] R730.53[医药卫生—临床医学]